VANCOUVER, CANADA – July 20, 2017 – Evasc Neurovascular Enterprises ULC announced today that Dr. David Ostrow, Carl Simpson, and Ang Zhao have joined its Board of Directors, each bringing a distinct skillset to the Board:
Dr. David Ostrow brings a wealth of clinical expertise to the Board. Dr. Ostrow was President and CEO of Vancouver Coastal Health Authority from 2009 until his retirement in 2014. He is a Fellow of the Royal College of Physicians of Canada and a Professor of Medicine at the University of British Columbia. He is the author or co-author of over 90 publications, abstracts or presentations.
Carl Simpson is an accomplished entrepreneur, leader, advisor, and investor in the medical and medical device arena and leverages more than 40 years’ experience in the field. He was a founder and VP of Research and Development at Advanced Cardiovascular Systems, which was sold to Ely Lily in 1984. After ACS, he continued to pursue his entrepreneurial passion, working to establish more than 25 medical device companies. Mr. Simpson is a founder and current managing director at Coronis Ventures, and he actively participates as a board member for multiple medical device companies.
Ang (Moses) Zhao, CPA, has more than 12 years’ experience in investment, financing, accounting, auditing, internal control and risk management, with PriceWaterhouseCoopers and Ceyuan Ventures. Currently, Moses is the Executive Director of SinoRich Capital. He holds a B.A. in public health administration from Fudan University, has a master’s degree in professional accounting, and a Canadian CPA/CMA.
“We are excited to welcome Dr. Ostrow, Mr. Simpson and Mr. Zhao to the Board. They bring a wealth of experience in the clinical, engineering and financial aspects for Medical Device companies that will help Evasc accelerate our progress on global commercialization of the eCLIPs device”, said Dr. Donald Ricci, President and Chief Executive Officer of Evasc.
In development since 2008, eCLIPs is a patented endovascular device designed to treat 95% of cerebral aneurysm cases and is currently targeted for use in challenging wide-neck bifurcations. eCLIPs combines the best properties of stents and diverters and can be used for coil retention and to enhance flow disruption. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac while protecting and providing a platform for endothelial growth across the bifurcation neck. To date, eCLIPs has been used to treat cerebral aneurysms in over 40 patients in Canada and 8 European countries.
Evasc Neurovascular is a privately held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc received approval for the use of eCLIPs in Canada under the Special Access Program in 2013 and received CE mark approval in 2015. Evasc is headquartered in Vancouver, Canada.
Evasc Neurovascular is on the web at www.evasc.com.
For more information, contact Scott Wilson at +1 (604) 742-3811, firstname.lastname@example.org.